Eli Lilly’ liver cancer treatment Cyramza (ramucirumab) has met its primary endpoint of overall survival (OS) and the secondary endpoint of progression-free survival (PFS) in the phase 3 Reach-2 study.
Original Article: Eli Lilly's Cyramza meets primary endpoint in phase 3 liver cancer trial